Evogene Ltd (NAS:EVGN)
$ 0.6251 -0.008 (-1.26%) Market Cap: 31.43 Mil Enterprise Value: 16.56 Mil PE Ratio: 0 PB Ratio: 3.68 GF Score: 54/100

Q1 2023 Evogene Ltd Earnings Call Transcript

May 18, 2023 / 01:00PM GMT
Release Date Price: $0.625 (-5.30%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to Evogene's First Quarter 2023 Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded, May 18, 2023.

Before we begin, I would like to caution that certain statements made during this earnings conference call by evidence management will constitute forward-looking statements that relate to future events, risks and uncertainties regarding business, strategy, operations and future performance and results of Evogene.

I encourage you to review Evogene filings with the U.S. Securities and Exchange Commission and read the note regarding forward-looking statements in today's earnings release, which states that statements made in the earnings release and in a similar way, on this earnings conference call they are not historical facts may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

For example, Evogene is using forward-looking statements in this call when it discusses the results of Biomica Phase I clinical trial for its

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot